DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Neupro (Rotigotine) - Summary

 
 



IMPORTANT: NEUPRO is for use on the skin only.

 

NEUPRO SUMMARY

Neupro is a transdermal system that provides continuous delivery of rotigotine, a non-ergoline dopamine agonist, for 24 hours following application to intact skin.

Parkinson's Disease (PD)

Neupro (Rotigotine Transdermal System) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.

The effectiveness of Neupro was demonstrated in randomized, controlled trials in patients with early-stage Parkinson's disease who were not receiving concomitant levodopa therapy as well as in patients with advanced-stage Parkinson's disease on concomitant levodopa.

Restless Legs Syndrome (RLS)

Neupro (Rotigotine Transdermal System) is indicated for the treatment of moderate-to-severe primary restless legs syndrome.


See all Neupro indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Neupro (Rotigotine)

Drug safety evaluation of rotigotine. [2012]
INTRODUCTION: Rotigotine, a non-ergolinic dopamine-receptor agonist, is currently approved as monotherapy in early idiopathic Parkinson's disease (IPD), in moderate to severe idiopathic restless legs syndrome (RLS) and as adjunct therapy to levodopa in advanced IPD... In addition, transdermal delivery is associated with local skin reactions, which are usually mild but may lead to a treatment discontinuation in a minority of patients.

Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. [2010]
This randomized, double-blinded, placebo-controlled trial (NCT00135993) assessed efficacy and safety of the dopamine agonist rotigotine in the treatment of idiopathic restless legs syndrome (RLS) over a 6-month maintenance period. A total of 505 eligible participants with moderate to severe RLS (IRLS sum score >or= 15) were randomly assigned to five groups to receive either placebo or rotigotine (0.5, 1, 2, or 3 mg/24 hr) delivered by once-daily transdermal patch (fixed-dose regimen)...

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. [2007]
Parkinson's disease and wearing-off type motor fluctuations... INTERPRETATION: In terms of change in absolute off time, rotigotine was

Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. [2007]
patients with early Parkinson disease... CONCLUSION: The rotigotine transdermal system consistently demonstrated

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. [2007]
(Neupro) is a novel dopaminergic agonist with 24-hour transdermal delivery... CONCLUSIONS: Transdermal rotigotine significantly improved "off" time in subjects

more studies >>

Clinical Trials Related to Neupro (Rotigotine)

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Gastroparesis [Recruiting]
The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with Gastroparesis. Hypothesis: Rotigotine will improve gastric emptying times.

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) [Recruiting]
The purpose of the study is to show that Rotigotine improves Restless Legs Syndrome (RLS) symptoms in subjects with moderate to severe RLS during both day and evening.

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy [Recruiting]
This trial is being conducted to assess the effects of Rotigotine over Placebo on improvement of Apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic ParkinsonĀ“s Disease.

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome [Recruiting]
This will be a multicenter, open-label, dose-escalation, Phase 2A study with multiple monotherapy administration of the Rotigotine transdermal system. The study will be conducted in adolescent subjects (13 to <18 years of age) with idiopathic Restless Legs Syndrome (RLS).

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients [Recruiting]
The purpose of this study is to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.

more trials >>

Reports of Suspected Neupro (Rotigotine) Side Effects

Drug Ineffective (12)Parkinson's Disease (12)Sopor (8)Pruritus (7)Somnolence (7)Dyspnoea (7)Atrial Fibrillation (7)Urticaria (6)Erythema (6)Fall (6)more >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014